Water. Desalination + reuse
Issue link: https://fhpublishing.uberflip.com/i/107143
BUSINESS coRpoRAte chAngeS Dow to BUIlD Ro mEmBRaNE plaNt IN HUzHoU, CHINa A world-class manufacturing facility for Dow FilmTec™ reverse osmosis (RO) elements for desalination and water reuse is to be built in Huzhou, China, the Dow Chemical Co announced on 7 June 2012. The new facility will be online in 2013. "This investment is directly aligned to our growth strategy to maximize value as a leading science company, benefiting our customers in China and the China economy while contributing to Dow's global growth," said Peter Sykes, president of Dow Greater China. "Dow Greater China is built on a solid foundation, and we're very confident about our ability to contribute to the China market and customer growth with a business focus which fits China's 12th Five-Year Plan." The proposed facility will deliver local supply security of cuttingedge technology for potable, non-potable and industrial water serving China. The facility will also serve as a sourcing point for global demand, boosting supply of Dow's products worldwide. The facility joins Dow's ultrafiltration manufacturing facility in Huzhou and ion-exchange resin facility in Qingpu, which supply global products. GE aND mEmSyS IN joINt mD DEvElopmENt aCCoRD Singapore-based membrane distillation (MD) specialist memsys clearwater Pte Ltd has entered into an agreement with GE to jointly develop the technology for the fast-growing oil and gas market. Under the terms of the agreement, GE will invest in testing the technology and in return receive an exclusive license for the use of the technology in these applications. GE has extensive experience in thermal and membrane system design, and an extended research capability through GE Global Research. For both companies, this agreement is spurred by the belief that the memsys MD technology is ideally positioned to support the rapid development of unconventional resource projects around the world and meet the rising demand for cost-effective water treatment technologies to reduce the environmental impacts of these types of projects. MD is a low-cost brine concentration technology that can replicate the conventional thermal evaporation process while using less energy and lowering the cost and the carbon footprint of evaporation. Decreasing energy consumption not only saves money and increases efficiency but also reduces emissions and has less of an impact on the environment. US$ 6.25 mIllIoN EqUIty INvEStmENt foR DESalItECH Reverse-osmosis (RO) innovator Desalitech Inc has secured an equity investment of U$$ 6.25 million led by Liberation Capital LLC, which will be used for business expansion and working capital. Liberation will also be supporting Desalitech with considerable project finance capital. Desalitech has commercialised its proprietary Closed Circuit Desalination (CCD™) technology as packaged-plant products for industrial and municipal water supply and wastewater treatment applications. Plants are available as capital equipment sales or as outsourced water treatment solutions. | 12 | Desalination & Water Reuse | August-September 2012 "Liberation Capital is providing the growth capital we need for product commercialization as well as the project finance that will allow us to create a service-oriented business model," said Nadav Efraty, Desalitech CEO. "As importantly, the deep industry domain knowledge brought by the Liberation team and their experience in growing global businesses will help us focus our strategy and scale our business as we grow." Rick Stover, Desalitech's executive vice president, said, "Nextgeneration CCD technology is a performance breakthrough for RO water treatment. Desalitech is now prepared to recruit top performers and become a major provider of high-recovery and water-reuse solutions in North America and around the world." HyflUx GIvEN loaN to BUy mEmBRaNES aND HIGH-pRESSURE pUmpS Singapore's Hyflux Ltd announced on 14 June 2012 that its whollyowned subsidiary, Hydrochem (S) Pte Ltd, has agreed a US$ 14.4 million loan with the Japan Bank for International Cooperation ( JBIC) for the purchase of key components for the Tuaspring Desalination Plant in Singapore. Key components to be purchased with this credit are seawater reverse-osmosis (SWRO) membrane elements manufactured by Toray Industries Inc and high-pressure pumps manufactured by Torishima Pump Mfg Co Ltd. These components will be purchased from Mitsui & Co Plant Systems Ltd. Caption This loan is cofinanced by Mizuho Corporate Bank Ltd, while Nippon Export & Investment Insurance will provide the buyer's credit insurance for the cofinanced portion. The loan is the first of its kind extended by JBIC to Hyflux Group following their memorandum of understanding on global collaboration on water projects signed in August 2009. It is also the first time that a buyer's credit loan has been secured for components for a Hyflux project. Hyflux was awarded the design, build, own and operate contract for Singapore's second SWRO project in March 2011. Tuaspring Desalination Plant, which is designed to produce 318,500 m3/d of desalinated water, will employ Hyflux's proprietary ultrafiltration membrane technology for pretreatment and a double-pass RO process. paRkSoN movES mIDDlE EaSt woRk BaCk to USa Parkson Corp of the USA announced on 15 June 2012 that it is consolidating the operations of its Middle East group into the international division to optimize the delivery of its water and wastewater treatment technologies to the rest of its customer base in other parts of the world. Since opening in 2007, Parkson's office in Dubai has enjoyed considerable success, especially in delivering environmentallyconscious package systems to industrial customers. More recently, Parkson has seen soaring demand in the Middle East for MaximOS™ disinfection systems and the newly redesigned DynaSand® EcoWash™ filtration system. One major achievement of the Dubai office was to collaborate on the design and construction of a state-of-the-art wastewater treatment plant in Rabigh, Saudi Arabia. The success of the membrane bioreactor facility illustrates Parkson's depth of knowledge on treatment processes and systems integration.